• Je něco špatně v tomto záznamu ?

Alpha-methyl CoA racemase (AMACR) reactivity across the spectrum of clear cell renal cell neoplasms

P. Rotterova, R. Alaghehbandan, J. Skopal, J. Rogala, M. Slisarenko, A. Strakova Peterikova, K. Michalova, DP. Montiel, M. Farcas, M. Ulamec, P. Stransky, O. Fiala, T. Pitra, M. Hora, M. Michal, K. Pivovarcikova, O. Hes

. 2024 ; 71 (-) : 152297. [pub] 20240324

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013315

a-Methylacyl coenzyme A racemase (AMACR) is traditionally considered to be a marker of papillary renal cell carcinoma. However, AMACR expression can be seen in other renal tumors. The aim of this study was to investigate AMACR immunoreactivity within the spectrum of clear cell renal cell neoplasms. Fifty-three clear cell renal epithelial tumors were used in assembling the following four cohorts: low grade (LG) clear cell renal cell carcinoma (CCRCC), high grade (HG) CCRCC, CCRCC with cystic changes, and multilocular cystic renal neoplasm of low malignant potential (MCRNLMP). Representative blocks were stained for AMACR, using two different clones (SP52 and OV-TL12/30). There were at least some AMACR immunoreactivity in 77.8 % and 68.9 % of CCRCCs (using SP52 and OV-TL12/30 clone, respectively). Moderate to strong positivity, or positivity in more than one third of the tumor (even weak in intensity) was detected in 46.7 % of CCRCCs using SP52 and in 48.9 % of CCRCC using OV-TL12/30 clone. The highest AMACR reactivity was observed in HG CCRCC (60 % by SP52 and 66.7 % by OV-TL12/30). Strong and diffuse AMACR positivity was detected in 8.9 % of all CCRCCs. AMACR immunoreactivity in MCRNLMP was 37.5 % (SP52 clone) and 25 % (OV-TL12/30 clone). We demonstrated relatively high expression rate of AMACR in CCRCC, while very variable in intensity and distribution. This finding may have diagnostic implications especially in limited samples (i.e., core biopsies), as AMACR positivity does not exclude the diagnosis of CCRCC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013315
003      
CZ-PrNML
005      
20240905134108.0
007      
ta
008      
240725e20240324xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.anndiagpath.2024.152297 $2 doi
035    __
$a (PubMed)38579443
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rotterova, Pavla $u Department of Pathology, Biopticka laborator, Pilsen, Czech Republic
245    10
$a Alpha-methyl CoA racemase (AMACR) reactivity across the spectrum of clear cell renal cell neoplasms / $c P. Rotterova, R. Alaghehbandan, J. Skopal, J. Rogala, M. Slisarenko, A. Strakova Peterikova, K. Michalova, DP. Montiel, M. Farcas, M. Ulamec, P. Stransky, O. Fiala, T. Pitra, M. Hora, M. Michal, K. Pivovarcikova, O. Hes
520    9_
$a a-Methylacyl coenzyme A racemase (AMACR) is traditionally considered to be a marker of papillary renal cell carcinoma. However, AMACR expression can be seen in other renal tumors. The aim of this study was to investigate AMACR immunoreactivity within the spectrum of clear cell renal cell neoplasms. Fifty-three clear cell renal epithelial tumors were used in assembling the following four cohorts: low grade (LG) clear cell renal cell carcinoma (CCRCC), high grade (HG) CCRCC, CCRCC with cystic changes, and multilocular cystic renal neoplasm of low malignant potential (MCRNLMP). Representative blocks were stained for AMACR, using two different clones (SP52 and OV-TL12/30). There were at least some AMACR immunoreactivity in 77.8 % and 68.9 % of CCRCCs (using SP52 and OV-TL12/30 clone, respectively). Moderate to strong positivity, or positivity in more than one third of the tumor (even weak in intensity) was detected in 46.7 % of CCRCCs using SP52 and in 48.9 % of CCRCC using OV-TL12/30 clone. The highest AMACR reactivity was observed in HG CCRCC (60 % by SP52 and 66.7 % by OV-TL12/30). Strong and diffuse AMACR positivity was detected in 8.9 % of all CCRCCs. AMACR immunoreactivity in MCRNLMP was 37.5 % (SP52 clone) and 25 % (OV-TL12/30 clone). We demonstrated relatively high expression rate of AMACR in CCRCC, while very variable in intensity and distribution. This finding may have diagnostic implications especially in limited samples (i.e., core biopsies), as AMACR positivity does not exclude the diagnosis of CCRCC.
650    12
$a racemasy a epimerasy $x metabolismus $7 D019998
650    _2
$a lidé $7 D006801
650    12
$a karcinom z renálních buněk $x patologie $x metabolismus $x diagnóza $7 D002292
650    12
$a nádory ledvin $x patologie $x metabolismus $x diagnóza $7 D007680
650    12
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a imunohistochemie $x metody $7 D007150
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
655    _2
$a časopisecké články $7 D016428
700    1_
$a Alaghehbandan, Reza $u Robert J. Tomsich Pathology and Laboratory Medicine Institute, Department of Anatomic Pathology, Cleveland Clinic, Cleveland, OH, USA
700    1_
$a Skopal, Josef $u Department of Pathology, Charles University in Prague, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Rogala, Joanna $u Department of Pathology, University Hospital Wroclaw, Poland
700    1_
$a Slisarenko, Maryna $u Department of Pathology, Charles University in Prague, Faculty of Medicine in Pilsen, Pilsen, Czech Republic; Department of Pathology, CSD LAB, Kyiv, Ukraine
700    1_
$a Strakova Peterikova, Andrea $u Department of Pathology, Biopticka laborator, Pilsen, Czech Republic; Department of Pathology, Charles University in Prague, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Michalova, Kvetoslava $u Department of Pathology, Biopticka laborator, Pilsen, Czech Republic; Department of Pathology, Charles University in Prague, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Montiel, Delia Perez $u Department of Pathology, Institute Nacional de Cancerologia, Mexico City, Mexico
700    1_
$a Farcas, Mihaela $u Department of Pathology, Charles University in Prague, Faculty of Medicine in Pilsen, Pilsen, Czech Republic; Onco Team Diagnostic, București, Romania
700    1_
$a Ulamec, Monika $u Department of Pathology and Cytology, University Hospital Centre Zagreb, Zagreb, Croatia
700    1_
$a Stransky, Petr $u Department of Urology, Charles University in Prague, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Fiala, Ondrej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Pitra, Tomas $u Department of Urology, Charles University in Prague, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Hora, Milan $u Department of Urology, Charles University in Prague, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Michal, Michal $u Department of Pathology, Biopticka laborator, Pilsen, Czech Republic; Department of Pathology, Charles University in Prague, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Pivovarcikova, Kristyna $u Department of Pathology, Biopticka laborator, Pilsen, Czech Republic; Department of Pathology, Charles University in Prague, Faculty of Medicine in Pilsen, Pilsen, Czech Republic. Electronic address: pivovarcikovak@fnplzen.cz
700    1_
$a Hes, Ondrej $u Department of Pathology, Biopticka laborator, Pilsen, Czech Republic; Department of Pathology, Charles University in Prague, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
773    0_
$w MED00166541 $t Annals of diagnostic pathology $x 1532-8198 $g Roč. 71 (20240324), s. 152297
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38579443 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134102 $b ABA008
999    __
$a ok $b bmc $g 2143247 $s 1225181
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 71 $c - $d 152297 $e 20240324 $i 1532-8198 $m Annals of diagnostic pathology $n Ann Diagn Pathol $x MED00166541
LZP    __
$a Pubmed-20240725
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace